cenobamate


( Last Updated : January 5, 2023)
Generic Name:
cenobamate
Project Status:
Pending
Therapeutic Area:
Epilepsy, partial-onset seizures
Manufacturer:
Paladin Labs Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0770-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
​​As an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​As an adjunctive therapy for the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.